Fresenius SE & Co KGaA (FRE) PT Set at €65.00 by Kepler Capital Markets

Kepler Capital Markets set a €65.00 ($75.58) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Tuesday. The firm currently has a buy rating on the stock.

Several other research firms have also recently weighed in on FRE. UBS Group set a €57.00 ($66.28) price target on shares of Fresenius SE & Co KGaA and gave the company a sell rating in a report on Monday, August 6th. DZ Bank reiterated a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Deutsche Bank set a €85.00 ($98.84) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, October 5th. Warburg Research set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, October 4th. Finally, Independent Research set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the stock. Fresenius SE & Co KGaA presently has a consensus rating of Buy and an average target price of €71.89 ($83.60).

FRA:FRE opened at €48.99 ($56.97) on Tuesday. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($69.95) and a twelve month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: Growth Stocks, What They Are, What They Are Not

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply